18 June 2013
Keywords: chmp, oks, novartis, biosimilar, neupogen, its, late-november
Article | 01 December 2008
At its late-November meeting, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 December 2008
17 June 2013
© 2013 thepharmaletter.com